SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is surging on massive speculative volume, fueled by escalating geopolitical tensions and fears surrounding the Strait of Hormuz closure by Iran, with the community actively debating short squeeze potential due to high cost-to-borrow and low share availability, despite some warnings about the company's debt.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as a significant stake disclosure by hedge fund MMCAP International, coupled with a recent corporate update teasing partnerships with "even bigger" companies, fuels strong community speculation. Investors are actively discussing the company's disruptive optical interposer technology and its potential to address high-speed data demands within the booming AI and photonics sectors, anticipating an imminent revenue ramp and major collaborations.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors await a critical city council vote on a major data center tax abatement, while robust community discussion highlights the company's strong capital structure, setting it apart from a peer's recent earnings and broader market reactions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as discussions are dominated by President Trump's recent military actions in Iran, sparking intense debate within the community regarding the conflict's strategic purpose versus claims of it being a distraction from domestic issues such as the Epstein files.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB Inc. is trending lower following its earnings report, where robust quarterly results were overshadowed by cautious forward guidance and news of executive departures, prompting community discussion on whether the significant sell-off is an overreaction or a justified response to slowing growth concerns within the software sector.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment Inc. is trending due to a sharp sell-off following a Raymond James downgrade tied to the recompete of a significant $1.4 billion Space Force contract. However, the community largely views this as an overreaction, actively buying the dip while highlighting strong drone demand amid global tensions and anticipating a positive earnings report.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings Inc. is trending sharply upward following Nvidia's multi-billion dollar strategic investment and partnership aimed at advancing optical interconnects for next-generation AI data centers. The community is excitedly discussing Lumentum's dramatic price appreciation and its pivotal role in the burgeoning AI infrastructure, despite some voicing concerns over its rapidly escalating valuation.

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Dave Inc - Ordinary Shares - Class A

Dave Inc. is trending following its strong Q4 '25 earnings report, which included substantial revenue and EPS growth and an increased $300 million share repurchase authorization. The community is actively discussing potential analyst upgrades and a short squeeze, believing the fintech is significantly undervalued given its robust financial performance and tight share float.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster Inc. is trending after reporting exceptionally strong Q4 earnings, significantly beating revenue and EPS estimates while achieving GAAP profitability. The community is actively discussing its strong gross margins, robust forward guidance, and the strategic acquisition of StereoLabs, which positions the company as a leading full-stack sensing and perception platform for the rapidly expanding Physical AI market.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp. is highly active following Nvidia's multi-billion dollar investment to advance optical networking and capacity for AI data centers. The community is buzzing, viewing this as strong validation for Coherent and the broader photonics sector's essential role in building next-generation AI infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BELGRADE, Mont., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 on Thursday, March 5, 2026, after the market close.Management will conduct an investor conference call on Thursday, March 5 at 5:00 p.m. Eastern Time (3:00 p.m. Mountain Time) to discuss these results and business outlook. Interested parties can access the conference call by dialing 1-800-245-3047 or 1-203-518-9765. The conference call will also be broadcast live on the Investor Relations section of our website at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=N02BFrEDLc6S5eqV_gdfOOOU5wVTV44aR6PDI1IgVtgzXqxX31sRHwRlr_ZmurVFUdS84oFnAAuvsiwCxqcm84z8x9L46jrSZyjfg0tpCJ294XTPO9wG4JiQci7tUuzo">https://ir.bridgeraerospace.com</a>.An audio replay of the conference call will be available through March 12, 2026, by calling 844-512-2921 or 412-317-6671 and using the passcode 11160880. The replay will also be accessible at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=N02BFrEDLc6S5eqV_gdfOOOU5wVTV44aR6PDI1IgVtjTMASZY8E7jr83HaSVOSBI2kWRzlYUPbPcrkrbBRqWzlqZv_-GHrvc30wZikDW6Af7vFPufBvNWECEQ2uHtYKS">https://ir.bridgeraerospace.com</a>.About Bridger Aerospace Based in Belgrade, Montana, Bridger Aerospace Group Holdings, Inc. is one of the nation’s largest aerial firefighting companies. Bridger provides aerial firefighting and wildfire management services to federal and state government agencies, including the United States Forest Service, across the nation, as well as internationally. More information about Bridger Aerospace is available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=N02BFrEDLc6S5eqV_gdfOOohjli0eZMnTlCkQ8vSv-oPi4XMb0jxgK5Ly7WdKxH573OCGYKjzJ9skc-lSpGm7xEjDWK5kNrkAd_Yjsf5sNL2zH3yWsDHUWO0SSvsbh81">https://www.bridgeraerospace.com</a>.Investor Contacts Alison Ziegler&nbsp; Darrow Associates&nbsp; 201-220-2678&nbsp; <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=eTkKc319XYtUVo7Xy1Q-h4Vj4ON6T7gcjfdSlxWyJkHZChwRufHiy1u9aw8V-uwKbVlIH44XDL-HejcSqVt96lt87GkLmb-c8D00fzTifso=">aziegler@darrowir.com</a><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/NewsRoom/AttachmentNg/d92b7f72-b6ac-47e5-a20b-62c2bd924efe"><img src="https://ml.globenewswire.com/media/d92b7f72-b6ac-47e5-a20b-62c2bd924efe/small/bridger-logo-jpg.jpg" alt="Primary Logo" width="150" height="45"></a>Source: Bridger Aerospace Group Holdings, Inc.Released February 26, 2026Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Bridger Aerospace Announces Schedule for its Fourth Quarter 2025 Earnings Release and Conference Call

Bridger Aerospace will release its 2025 financial results and host a call on March 5, 2026.

Others

VANCOUVER, British Columbia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that its drone subsidiary ZenaDrone has initiated the development of a quantum navigation system designed to enable secure drone operations in GPS-denied and satellite-compromised environments. The system will initially support ZenaDrone 1000, the company’s multifunction heavy-lift drone for use in defense applications including ISR (Intelligence, Surveillance and Reconnaissance), specialized cargo, and border patrol. Future scalability is also planned across the company’s IQ series drone platforms.“The ability to operate autonomously in GPS-denied environments is an operational imperative for modern defense,” said Shaun Passley, Ph.D., ZenaTech CEO. “We are committed to supporting U.S. defense and national security interests with technology that performs where conventional systems fail. We see quantum navigation as a cornerstone capability that will define the next generation of autonomous systems for defense, and we are making the strategic investments in the R&amp;D needed to enable our future leadership as the industry evolves."<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=t30Oc0dC6GuC-y49AwmieDPVBFQRoPhaKZ7CdtyhxVMKd5BSEPOZBTM62xHfL1u-apqwviYAbvyXU6Z8X39kGC-xMw14HPErCBUHLvLib7uLKRCrD_mWwEFXp-P_7qpJ-53lSZBezzsIs8mPYUemkyEdgish_ZRCypjQ5TQSreYAQv3pjM_ymWt9B4Af6jm7WGYfWtbQaPk_GCNS5OB3nRfH7nfnYDfxBaYv7gLUXwhpLRlECfvSifrIjPr9exfCTPScojySF1tu1SdM4XsGsw==">Quantum navigation systems</a> are considered next-generation, self-contained and ultra-precise motion sensing systems that enable reliable navigation without GPS by using quantum physics–based principles and sensors. As defense operational landscapes evolve, defense missions increasingly face environments where GPS and satellite signals cannot be relied upon, whether due to jamming, spoofing, or other contested conditions. These navigation systems fuse quantum inertial measurement with AI-driven path correction, enabling sustained and accurate positioning over extended mission periods without reliance on external signals. Quantum navigation can also benefit commercial drones operating in GPS-challenged environments such as in dense urban corridors, indoor industrial facilities, underground sites, and long-range BVLOS (Beyond Visual Line-of-Sight) missions.The Company’s R&amp;D team is at the initial stages of development focused on incorporating this capability into the ZenaDrone 1000, and management expects to advance through research and development, drone integration, and testing phases which will involve multifunctional teams in due time. The quantum navigation system is expected to be integrated into ZenaDrone’s defense and commercial drone platforms, enhancing capabilities for surveillance, critical infrastructure inspection, and defense missions.The ZenaDrone 1000 is engineered as an advanced AI-powered VTOL heavy-lift platform optimized for defense use, offering ISR capabilities including real-time surveillance, tactical reconnaissance, and secure data collection, alongside cargo transport and mission-critical payload delivery. Its modular design allows rapid configuration for multi-mission operations in high-risk environments, from infrastructure monitoring to operational logistics support.About ZenaTech<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=YwDM3KboJwYxcypW11TvgOZ6m09x0DvluRfeFSpflNi7fxAGMTAnoYakpmixgTw4nQ-oTe14O-_-um_nhEK1-A==">ZenaTech</a> (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=FFBRcJmSw7QknHZWxvZNZA320BcHWvAMIXs3fY1pnyHwUsG8TZi-zIv7TCKQM1q4iAVQGY6J406eGzl7STJBUyxpDBlDWu5JhXBH79KfDgw=">Drone as a Service</a> (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical applications for business, government and defense. Since 2017, the Company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive speed, accuracy, and cost savings. The Company operates through global offices in North America, Europe, Taiwan, and UAE, and is growing its DaaS business and global network of locations through acquisitions.About ZenaDrone&nbsp;&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=5as5ZK2D3u0lLxGZrfOUsUAmZhbt-D2gvcwrWvjNGAPWCONfMcJDywjCMa9o0Le6XO6sMQ9j3kp61btK5tswnQ==">ZenaDrone</a>, a wholly owned subsidiary of ZenaTech, develops and manufactures autonomous drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for surveying, monitoring, inspection, tracking, process automation, and defense applications. Currently, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=5as5ZK2D3u0lLxGZrfOUsU8SxzqDC_MDqVZpoyjUQTJxCw4AaGO5352u9jCHQ6OEqEBeHd83WFu6LX7aYVr5WP_aElUGI1LB0a0-Q0wOGfsIbVFOSp57wgQuYJFQWtSM">ZenaDrone 1000</a> drone is used for crop management applications and critical field cargo applications in the defense sector, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=qdzCB6DM3_6tmhGxqO7p07vkX4ToIsmPhhPBUf4wqm1oVjNQCtlRfkvA72726DWSfxzrpokUljpOl6K6zv5G04IVM4oOOtbwfEAjTQ43nIIWpApBwVIpFTpb3lVNhZs5">IQ Nano</a> indoor drone is used for inventory management and security in the warehouse and logistics sectors, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=8lSTUuyLRTV86g6f8WGypGUddoHZ15MDFc80KP0DBzZMRFc7NsQ2VYhdDNGQDZcC5_tejGmHq-eOKUL5ob7YNptF2JCGqOd8zNhc5d4mHzsY-PPGHnl5eobN_-MHdjR3">IQ Square</a> is an outdoor drone designed for power washing and inspections use in commercial and government sectors, and the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=hZr0V9naO6MP2VIqVXS_ciIxAMTpJZ0kamVpnX-6YZkOMEtaOjuow224GkB9LCf7Fr5P8ndRWk9eGRA9KThZHt2LUXwMDEpn_q8ZwO-rKzk=">IQ Quad</a> is for land surveys.Contacts for more information:Company, Investors, and Media:Linda MontgomeryZenaTech312-241-1415<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=1Jb3kEMv0xuLcA5zRslO1PUShH1BzV_1QoMhRcbDRDtxM0f05ln9G9yICl2MrJACw2p40adVfXbM_P04tM_QSRugGS952eeHFtzezcBAcws=">investors@zenatech.com</a>Investors:Michael MasonCORE IR<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=1Jb3kEMv0xuLcA5zRslO1PUShH1BzV_1QoMhRcbDRDsjXtUWLjQQ7nhtJfgyEbapEpOqYWNQxuPryO9YD9XbAnLuD3tsN8QCUnSTuAkw3TE=">investors@zenatech.com</a>Safe HarborThis press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. &nbsp;Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity;&nbsp;ZenaTech's ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square and IQ Nano;&nbsp;ZenaTech's ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and it’s needs for additional financing;&nbsp;ZenaTech’s intention to grow the business and its operations and execution risk;&nbsp;expectations with respect to future operations and costs;&nbsp;the volatility of stock prices and market conditions in the industries in which ZenaTech operates;&nbsp;political, economic, environmental, tax, security, and other risks associated with operating in emerging markets;&nbsp;regulatory risks;&nbsp;unfavorable publicity or consumer perception;&nbsp;difficulty in forecasting industry trends;&nbsp;the ability to hire key personnel;&nbsp;the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months;&nbsp;ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments;&nbsp;investment capital and market share; the ability to complete any contemplated acquisitions;&nbsp;changes in the target markets;&nbsp;market uncertainty;&nbsp;ability to access additional capital, including through the listing of its securities in various jurisdictions;&nbsp;management of growth (plans and timing for expansion);&nbsp;patent infringement;&nbsp;litigation;&nbsp;applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks ‎‎‎and uncertainties disclosed under the ‎heading “Risk Factors“ ‎‎‎‎in the Company’s Form F-1, Form 20-F and other filings filed ‎‎‎with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=f7-VoCZxouyhrInG3iUKSCLfQvM_iRAb7q8joNxWrT9DUvxmWWSbrwVxQgcAxhBdss1lbN_Ko9mRKDhR15zLlpGFV3JqTIrcJi5Ci10l0Ibw9xvqPwE2KOA12Ji-S7xsHsXeO7bnMGoMYcZVTGUAJ83ffleLDgC9xjf_EY5Ak5rtP3As8YHf7fDGh617BJ5YBiYDGKabs8qMb-wXxx-NTFNpZKUSH_ThMkyOEubwX94=">www.sec.gov</a>. The Company undertakes ‎‎‎no obligation to update forward-‎looking ‎‎‎‎information except as required by applicable law. Such forward-‎‎‎looking information represents ‎‎‎‎‎managements’ best judgment based on information currently available. ‎‎‎No forward-looking ‎‎‎‎statement ‎can be guaranteed and actual future results may vary materially. ‎‎‎Accordingly, readers ‎‎‎‎are advised not to ‎place undue reliance on forward-looking statements or ‎‎‎information.‎Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

ZenaTech’s ZenaDrone Initiates Defense-focused Quantum Navigation System for GPS-Denied Drone Operations

ZenaTech's ZenaDrone starts developing quantum navigation for GPS-denied defense drone operations.

Tradr 2X Long SNDK Daily ETF Becomes Fastest Growing ETF of the Past 12 MonthsNEW YORK, Feb. 24, 2026 /PRNewswire/ -- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4626465-1&amp;h=528375679&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>,&nbsp;a provider of ETFs designed for sophisticated investors and professional traders, today announced that the Tradr 2X Long SNDK Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4626465-1&amp;h=1853350105&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fsnxx&amp;a=SNXX">SNXX</a>)&nbsp;has become the fastest growing ETF launched in the past 12 months, as measured by average assets gathered per day since inception.Launched on January 27, 2026, SNXX amassed $650 million in assets under management in just 24 days, averaging over $27 million in net new AUM per day since inception as of February 20, 2026. The fund is now the fifth-largest single-stock ETF in the U.S. market, behind only TSLL, NVDL, GGLL and MUU, according to data from Bloomberg.SNXX seeks to deliver 200% of the daily performance of Sandisk Corp. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradrs-snxx-surges-to-650-million-in-under-a-month-setting-industry-growth-record-302696236.html#financial-modal">SNDK</a>), offering traders a capital-efficient vehicle to express high conviction views without the need for margin accounts or options strategies.The strong adoption of SNXX follows continued demand for Tradr's recently launched single-stock ETFs. The Tradr 2X Long LITE Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4626465-1&amp;h=3820639836&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Flitx&amp;a=LITX">LITX</a>) has gathered approximately $200 million in AUM within its first month, while the Tradr 2X Long WDC Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4626465-1&amp;h=361472615&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fwdcx&amp;a=WDCX">WDCX</a>) has accumulated approximately $40 million over the same period (all data as of February 20, 2026)."The speed of adoption we're seeing in our recent launches demonstrates real unmet market demand," said Russell Tencer, President of Tradr ETFs. "Traders and active investors are voting with their capital for the precision trading products Tradr is delivering."Tradr ETFs is the pioneer of single-stock ETF exposures in the U.S. and is currently the fastest growing provider in the category. With a focus on precision tools for active market participants, Tradr empowers traders to access amplified exposure to individual stocks in a transparent, exchange-traded structure.Tradr's lineup of 69 leveraged ETFs represents $2.7 billion in assets under management. For detailed information on Tradr ETFs and the significant risks involved with leveraged ETFs, please visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4626465-1&amp;h=2914380782&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>.About Tradr ETFs <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4626465-1&amp;h=528375679&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>&nbsp;are designed for sophisticated investors and professional traders&nbsp;who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs.IMPORTANT RISK INFORMATIONTradr ETFs are for sophisticated investors and professional traders with high conviction views and are very different from most other ETFs. The Funds are intended to be used as short-term trading vehicles and pursue leveraged investment objectives, which means they are riskier than alternatives that do not use leverage because the Funds magnify the performance of their underlying security. The volatility of the underlying security may affect a Fund's return as much as, or more than, the return of the underlying security.Investors in the fund should: (a) understand the risks associated with the use of leverage; (b) understand the consequences of seeking inverse and leveraged investment results; (c) for short ETFs, understand the risk of shorting; (d) intend to actively monitor and manage their investment. Fund performance will likely be significantly different than the benchmark over periods longer than the specified reset period and the performance may trend in the opposite direction than its benchmark over periods other than that period.Leverage increases the risk of a total loss of an investor's investment, may increase the volatility of the Funds, and may magnify any differences between the performance of the Funds and their reference security. The Funds seek leveraged investment results for a specific period (daily, monthly or quarterly). The exact exposure of an investment in the Fund intra-period will depend upon the movement of the reference security from the end of the prior period until the time of investment by the investor.The Fund will not attempt to position its portfolio to ensure it does not gain or lose more than a maximum percentage of its net asset value on a given trading day. As a consequence, investors in a Fund that seeks two times daily performance would lose all of their money if the Fund's underlying security moves more than 50% in a direction adverse to the Fund on a given trading day.ETFs involve risk including possible loss of the full principal value. There is no assurance that the Fund will achieve its investment objective. Principal risks and other important risks may be found in the prospectus. Past performance does not guarantee future results.ETF shares are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds. This and other important information about the Fund is contained in the Prospectus, which can be obtained by visiting <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4626465-1&amp;h=2914380782&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>. The Prospectus should be read carefully before investing.Distributed by ALPS Distributors, Inc, which is not affiliated with AXS Investments or its Tradr ETFs. AXI000873SOURCE Tradr ETFsNote: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Tradr's SNXX Surges to $650 Million in Under a Month, Setting Industry Growth Record

Tradr 2X Long SNDK Daily ETF Becomes Fastest Growing ETF of the Past 12 Months

- Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales -- Rasayana to assume all responsibility and costs for SYN-020 development and commercialization -ROCKVILLE, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported the out-licensing of SYN-020, to Rasayana Therapeutics, Inc., a privately-held company targeting the Gut-Organ axis biology to discover and deliver transformative gut-targeted medicines for patients with chronic inflammatory diseases.&nbsp;SYN-020 is a recombinant bovine intestinal alkaline phosphatase (IAP) produced under cGMP conditions and formulated for oral delivery to the small intestine. It is designed to reduce fat absorption and intestinal inflammation; tighten the gut barrier to mitigate leaky gut; and promote a healthy microbiome. These modes-of-action mean SYN-020 has the potential to address multiple metabolic and inflammatory disorders and diseases associated with aging. SYN-020 was well tolerated in Phase 1 clinical studies and is now poised to enter Phase 2 clinical testing with Rasayana.“We are extremely pleased to complete the license of SYN-020 to Rasayana, which will enable the advancement of this important GI asset from our portfolio while we focus on our lead pancreatic cancer program, VCN-01,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We believe SYN-020 is a highly versatile asset with therapeutic opportunities in multiple high-value indications arising from GI dysfunction. The Rasayana team and advisors are world leaders in IAP and its clinical applications, and they are well positioned to advance SYN-020 development, ideally delivering benefits for patients and value for Theriva shareholders.”&nbsp;“We are thrilled to partner with Theriva Biologics on the development of SYN-020,” said Vidisha Mohad, Founder and CEO of Rasayana Therapeutics. “SYN-020 offers a fundamentally innovative approach to addressing gastrointestinal dysfunction and its systemic health implications. Having worked on SYN-020 research during my postdoctoral training at Harvard, I have deep conviction in its underlying biology, scientific rigor, and therapeutic potential. Importantly, its cost-effective profile reflects our shared commitment to making transformative treatments accessible to patients who need them most. At Rasayana, we are focused on advancing therapies that target the Gut-Organ Axis to extend healthspan. SYN-020’s novel biology, strong safety profile, and compelling clinical data make it an ideal fit for our pipeline. We look forward to building on Theriva’s foundational work and accelerating this program to deliver meaningful outcomes for patients worldwide”.Under the terms of the agreement, Rasayana is granted an exclusive, worldwide license, with the right to sublicense, to develop and commercialize SYN-020 for therapeutic and diagnostic use. Theriva received a $300,000 up-front payment at signing and is eligible for up to $16M in development and regulatory milestones, tiered single digit royalties on net product sales, and up to $22M in milestones payable upon achievement of certain annual aggregate net sales. Rasayana will assume all responsibility and costs for SYN-020 development and commercialization.&nbsp;About Theriva™ Biologics,&nbsp;Inc.Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; and (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. For more information, please visit Theriva Biologics’ website at&nbsp;www.therivabio.com.&nbsp;About Rasayana Therapeutics, Inc.Rasayana Therapeutics, Inc. is a biotechnology company targeting the Gut-Organ axis biology to address chronic inflammatory diseases. The company is pioneering a new class of gut-inflammation targeting therapies for gastrointestinal, cardiometabolic, and neurodegenerative diseases. Rasayana’s mission is to develop novel, cost-effective medicines that extend healthspan and improve quality of life for patients globally. For more information, visit Rasayana Therapeutics website at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=hLZTfPu2_0SymExk02qvUbsHQ8p-vzyMwruJmpooYqOW89Jp-kMpNRBCkyuLct-aQ1rNR0NhLwOo3WO03RLPjHGEKhHV6et5B6zWcDjISACDR3DgYde0lTEIZ5vW-puz">www.rasayanatherapeutics.com</a>Forward-Looking StatementThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding SYN-020 having the potential to address multiple metabolic and inflammatory disorders and diseases associated with aging; SYN-020 being poised to enter into Phase 2 clinical testing with Rasayana; enabling the advancement of this important GI asset; SYN-020 being a highly versatile asset with therapeutic opportunities in multiple high-value indications arising from GI dysfunction; and Rasayana being well positioned to advance SYN-020 development and deliver benefits for patients and value for Theriva shareholders; and SYN-020’s therapeutic potential accelerating the SYN-020 program to deliver meaningful outcomes for patients worldwide; and Theriva receiving up to $16M in development and regulatory milestones, tiered single digit royalties on net product sales, and up to $22M in milestones payable upon achievement of certain annual aggregate net sales . Important factors that could cause actual results to differ materially from current expectations include, among others, Rasayana’s ability to reach clinical milestones when anticipated including entering into Phase 2 clinical testing of SYN-020 , the ability generate clinical data that establishes SYN-020 may deliver benefits for patients and have therapeutic potential; Rasayana’s ability to achieve development and commercialization milestones as well as sales that result in payments to Theriva; SYN-020 and the Company’s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results; the ability to complete clinical trials on time and achieve the desired results and benefits; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s and Rasyana’s ability to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of the Company’s and Rasayana’s products, developments by competitors that render such products obsolete or non-competitive, the ability to maintain license agreements, the continued maintenance and growth of the Company’s patent estate, the ability to continue to remain well financed and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.For further information, please contact:Investor Relations: Kevin Gardner LifeSci Advisors, LLC kgardner@lifesciadvisors.comSource: Theriva Biologics, Inc.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications

Theriva Biologics licenses SYN-020 to Rasayana for $300k upfront and up to $38M in future milestones.

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong on Saturday, 07 February 2026 –- Preclinical data will highlight synergistic antitumor activity for the combination of topotecan and VCN-01 that may improve outcomes in refractory retinoblastoma patients with difficult-to-treat vitreous seeds -&nbsp;ROCKVILLE, Md. and BARCELONA, Spain, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced an invited presentation of clinical outcomes and safety data from the investigator sponsored Phase 1 clinical study (NCT03284268) evaluating the safety and tolerability of two intravitreal injections of VCN-01 (zabilugene almadenorepvec) in pediatric patients with intraocular retinoblastoma that was refractory to systemic, intra-arterial, or intravitreal chemotherapy, and for whom enucleation was the only recommended treatment. Preclinical data describing the synergistic antitumor effects observed when topotecan (a standard of care chemotherapy for retinoblastoma) is coadministered with VCN-01 will also be presented. These data will be presented during a retinoblastoma focused session at the upcoming Asia-Pacific Academy of Ophthalmology (APAO) Congress (held in conjunction with the 37thAnnual Scientific Meeting Hong Kong Ophthalmological Symposium) taking place in Hong Kong, China, 5-8 February 2026.&nbsp;Details of the presentation can be found <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=tNHDcbYkw6QgsozmQVCV8LQ4aTYsU_XNvjMA_g5TstEs-pckD_WX3j9BnnaHV3_z_8or3c9jjqdEB_nzrNUBX_jnp8z0HlzdOtuLudXTyKWHRFH-9eJtNAXRMj_D30Uj">online</a> and below.<ul><li>Presenting Author: Dr. Jaume Català-Mora, Pediatric Ophthalmologist, Sant Joan de Déu-Barcelona Children’s Hospital</li><li>Title: Update on Oncolytic Adenovirus VCN-01 Trial in Retinoblastoma</li><li>Session: 0211 Retinoblastoma in Association With Asian Retinoblastoma Group</li><li>Date &amp; Time: Saturday 07 February, 2026, at 4:46 PM HKT (3:46 AM US EDT)</li><li>Location: Rooms S224-225, Level 2, Hong Kong Convention and Exhibition Centre (HKCEC) &nbsp;</li></ul>“We are very pleased with the on-going international interest in the novel clinical and preclinical findings by our collaborators treating retinoblastoma patients at Sant Joan de Déu-Barcelona Children’s Hospital,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “Effective treatment of refractory retinoblastoma with vitreous seeds remains a significant unmet medical need for pediatric patients with this condition worldwide. Based on our previously reported Phase 1 clinical <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=ndEUifZXBX0beJKpblsn4l3WNy9v6SPzYN6472Z3tMuJHqxLesgsKvlFh8uhvvcve7VvQloR2cb6CQLkjepQg6nwP98Ywnl5KBtO-ct4zKeDD8Jz0o3wHfOvKHaNIGeu">data</a>, and the emerging preclinical findings, we believe that the intravitreal combination of VCN-01 and topotecan provides an exciting new opportunity to address this challenge and help preserve the eyes and quality-of-life of children with this rare but devastating cancer. VCN-01 has Orphan Drug and Rare Pediatric Disease designations for the treatment of retinoblastoma, and we are currently refining a potential pivotal clinical trial design in this indication for discussion with regulatory agencies.”About VCN-01VCN-01 (zabilugene almadenorepvec) is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive barrier to cancer treatment. This unique mode-of-action enables VCN-01 to exert multiple antitumor effects by (i) selectively infecting and lysing tumor cells; (ii) enhancing the access and perfusion of co-administered chemotherapy products; and (iii) increasing tumor immunogenicity and exposing the tumor to the patient’s immune system and co-administered immunotherapy products. Systemic administration enables VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered to over 140 patients to date in clinical trials of different cancers, including PDAC (in combination with chemotherapy), head and neck squamous cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma (by intravitreal injection). More information on these clinical trials is available at Clinicaltrials.gov. VCN-01 has Orphan Drug designation from the EMA and both Orphan Drug designation and Fast Track designation from the FDA for the treatment of pancreatic cancer. VCN-01 also has Orphan Drug designation and Rare Pediatric Diseases designation from the FDA for the treatment of retinoblastoma.&nbsp;About RetinoblastomaRetinoblastoma is a tumor that originates in the retina and is the most common type of eye cancer in children. It occurs in approximately 1/14,000 - 1/18,000 live newborns and accounts for 15% of the tumors in the pediatric population &lt; 1 year old. The average age of pediatric patients at diagnosis is 2, and it rarely occurs in children older than 6. In Europe, retinoblastoma has an estimated incidence rate of 1 per 13,844 live births (14.1 per million children under the age of 5) with approximately 300 children diagnosed per year (<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=bdwE4r7sy1MWwrIxf22JOGA7c7zt9J7zsbC2MgiwMD8ROr7SJbrucThnwSGxmDz3MR6uvdjupNm4w-W6JM2T5_ku9I7MZPAeSsHo5R3xqvYwAeWlPPIsoPoud3fUA4hI7f9FTUupCfakveniiQ3-dA==">Stacey et al. 2021</a>). Preserving life and preventing the loss of an eye, blindness, and other serious effects of treatment that reduce the patient’s life span or the quality of life remains a challenge. In addition, children with retinoblastoma have been more likely to lose their eye and die of metastatic disease in low-resource countries.&nbsp;About Theriva™ Biologics, Inc.Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L. , has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidates are: (1) VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients); and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=dhFmQsJ81g_9OUj8i5TBL_CFPWIb7PtqMyHERYhfHsp6p66lc6VlPfbfa-7P-87mJe7mfoiWVuHGo4O2RW3qYaNVBN7de2bMxaS2kOzZKz0=">www.therivabio.com</a>.&nbsp;Forward-Looking StatementThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding preclinical data highlighting synergistic antitumor activity for the combination of topotecan and VCN-01 that may improve outcomes in refractory retinoblastoma patients with difficult-to-treat vitreous seeds; the intravitreal combination of VCN-01 and topotecan providing an exciting new opportunity to address the challenge of effective treatment of refractory retinoblastoma withvitreous seeds retinoblastoma and a potential pivotal clinical trial design in retinoblastoma These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to design a pivotal clinical trial in retinoblastoma for discussion with the FDA; VCN-01’s ability to have positive results in future trials for the treatment of retinoblastoma and other therapeutic benefits; the Company’s ability to reach clinical milestones when anticipated including enrolling the expected number of patients in each trial; the Company’s product candidates, including VCN-01, demonstrating safety and effectiveness, as well as results that are consistent with prior results; the ability to complete clinical trials on time and achieve the desired results and benefits, continuing clinical trial enrollment as expected; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of the Company’s products, developments by competitors that render such products obsolete or non-competitive, the Company’s ability to maintain license agreements, the continued maintenance and growth of the Company’s and VCN’s patent estate, the ability to continue to remain well financed, and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.For further information, please contact:Investor Relations: Kevin Gardner LifeSci Advisors, LLC kgardner@lifesciadvisors.comSource: Theriva Biologics, Inc.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026

Theriva Biologics to present VCN-01 Phase 1 and preclinical data for retinoblastoma at APAO 2026.

VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces it has won the 2026 Most Prolific and Proficient Acquirer Award from&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=ik4gzjPaW19k3_Xf6qJQH9OMyk23lRy7143mMcnqdPhaZbw4aF1qyU9qHU1yTbAKvVTgADSuBP4L523LRr-a3rAKEI7pGqu9i9Hj6uU8BOE=">Morrissey Goodale</a> – a renowned management consulting and advisory firm exclusively serving the architecture, engineering, and environmental (AE) industry. The award is part of its Excellence in Acquisitive Growth Awards Series and recognizes ZenaTech’s disciplined and accelerated acquisition strategy, acquiring 18 US firms in the AE sector as part of its 20 global DaaS acquisitions in 2025.“This award validates our strategy to create value by acquiring established land survey companies and integrating drone-based data capture, automation, and analytics into their existing operations,” said Shaun Passley, Ph.D., ZenaTech CEO. “By purchasing firms that already have licensed professionals and long-standing client relationships in commercial and municipal markets, we gain immediate cash flow while we integrate drone technology. The strategy combines a fragmented, succession-driven industry roll-up opportunity with vertical integration—improving efficiency, expanding margins, and transitioning traditional surveying into higher-value, recurring Drone as a Service revenue streams.”The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=cSICbCN6YR87XtHPfNzti2_wR55wwp_wO8yYWJs0ekuS8USfsqA67GLbeOrn5aSDwcPaF9xLsXVR663a5eGszSjMHs0Y4SJRwYns2fHjP4GgBk80nc6gkzsgi37_1woPX5N9beravi5Jkh9lGuG0Wthn-wpZZ1oOwXABi5fKxHg=">Most Prolific and Proficient Acquirer Award</a>, presented annually by Morrissey Goodale, recognizes the firm completing the most US-based acquisitions in the prior year. The award celebrates disciplined deal execution, strategic growth, and leadership in industry consolidation. In connection with the award, Morrissey Goodale donates to a charitable organization chosen by the recipient. This year, ZenaTech has designated The Hospital for Sick Children (SickKids), Canada’s most research-intensive hospital and largest center dedicated to improving children’s health, as the beneficiary.ZenaTech’s Drone as a Service business platform provides business and government clients with on-demand or subscription-based access to faster and superior drone-based services for a host of surveying, inspection, maintenance, power washing, inventory management, and precision agriculture services, without the capital costs or operational burdens of ownership. By&nbsp;acquiring&nbsp;established, profitable service companies currently using low-tech processes and ripe for drone innovation, ZenaTech is building a global, multi-service DaaS network of locations in communities anchored by existing customers and revenue, for next-gen drone integration designed for speed, precision, data, and safety benefits.&nbsp;The company is continuing to build its global business and network of locations as well as its integration of drones and new services.&nbsp;About ZenaTech<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=MEnxrgP_FntnYSMTju7ZGqXo2gFqCeJvRoiZmC4tJaFIlzEHq-3-VCTtP7O7glsUlpiFL-iv6fE_3bqPNTMhOg==">ZenaTech</a> (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=MCUBnMAY6oHAko-rQqHs28ijlohBikbAV7lLQZPDjlEKJodGU3Zano90ykJ9QDkWfdL_0ysemCr1tzR93Kxl-97WuZZw4tOUbX99LkrrA6E=">Drone as a Service</a> (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical applications for business, government and defense. Since 2017, the Company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive speed, accuracy, and cost savings. The Company operates through global offices in North America, Europe, Taiwan, and UAE, and is growing its DaaS business and global network of locations through acquisitions.About ZenaDrone<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=E-ao7M8uuBA11s9lGeVDD1kKmY0dURXp5j71KViTLbN9Fd7EQeRFcT_16-RN0VWiHqtsvZD4SQB_VpbK5sQZ2g==">ZenaDrone</a>, a wholly owned subsidiary of ZenaTech, develops and manufactures autonomous drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for surveying, monitoring, inspection, tracking, process automation, and defense applications. Currently, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=E-ao7M8uuBA11s9lGeVDDyjMcJJTwBq7E2wNUwq6r9JtuRfG8K9D63-PJRTPfal5wd92PFk7pZgSzLJRioSY9bRpnR5Szud4U0SMomphkxwXto13nzATT6EYG8LzE3C3">ZenaDrone 1000</a> drone is used for crop management applications and critical field cargo applications in the defense sector, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=hhIpzYzVJ6g9wXIhMt4BrB1gMCl-5CIzwYGo47I7HxcQ5GR5CL2tdkAXCyHZvlkNyt90zXbgPLqKPwsMFGYBvwvN08L7l20du5j35FSi_Jwxt3dKTB_TPPLqVSjccI6F">IQ Nano</a> indoor drone is used for inventory management and security in the warehouse and logistics sectors, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=nv3KrjLlQEu1-2NUNjoy1vG--Y5iZb2MuJ3EPcwlx9wUE9k6tbdhnVWx9A2DjYIQzG-O4CWuSXKH54Mz1umIekQYNlpu-0A65fJRL2NvGiVDscP6ywy_bbl2zpkGMxkf">IQ Square</a> is an outdoor drone designed for power washing and inspections use in commercial and government sectors, and the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=1oshbszah8WjGRECBfpgz_RH0OsnsUWo8ybYgFchvS7ReKVltROst4nx0WrfvU91RNods1j5wTY_sxA9xw6d3He3AD-xprnTJ9MqbfJVNPw=">IQ Quad</a> is for land surveys.Contacts for more information:Company, Investors, and Media: Linda Montgomery ZenaTech 312-241-1415 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=R2tkTqTWNhv23vPDgZjBLg4LOVHPrSBQHscCZUUy3zvJQhGXHgVq7XorAiC5DokPMX6dFLvZAF_D32-eqQgiJ3-GIPx1-PUvL7CaBMPy2vw=">investors@zenatech.com</a>Investors: Michael Mason CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=R2tkTqTWNhv23vPDgZjBLg4LOVHPrSBQHscCZUUy3ztHi64BxAo__yfFs1V1ivios-N_mNdq_sSVFlfq_f78WePajCMHYw1ESehBOQ-IJE8=">investors@zenatech.com</a>Safe HarborThis press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech's ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square and IQ Nano; ZenaTech's ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and it’s needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks ‎‎‎and uncertainties disclosed under the ‎heading “Risk Factors“ ‎‎‎‎in the Company’s Form F-1, Form 20-F and other filings filed ‎‎‎with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=98zcgVc3wQFUbsUk9GdezN10uLkDsxn9dIkYqZIrZZ_p07jDCWetDa17nxERDdi87TyLnrtWY9DWYQ2gBPK69HqQU3jf2SPU0r9diIJoTPob-y1W_9QmGAStx4I9R_3Ywtz0C-4B6-ESqFK54ZCULuqjAi1HazAdqYxGbTiBf37f1t2t1sGE31wPXHPdj76ko3CkPyv51HnGd-6wCs3hqzWHSJZza8iiolrgROWPeDA=">www.sec.gov</a>. The Company undertakes ‎‎‎no obligation to update forward-‎looking ‎‎‎‎information except as required by applicable law. Such forward-‎‎‎looking information represents ‎‎‎‎‎managements’ best judgment based on information currently available. ‎‎‎No forward-looking ‎‎‎‎statement ‎can be guaranteed and actual future results may vary materially. ‎‎‎Accordingly, readers ‎‎‎‎are advised not to ‎place undue reliance on forward-looking statements or ‎‎‎information.‎Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

ZenaTech Wins the Morrissey Goodale 2026 Most Prolific and Proficient Acquirer Award for Growing its Drone as a Service Network

ZenaTech wins the 2026 Most Prolific Acquirer Award for its rapid drone and AE sector expansion.

VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces that its ZenaDrone subsidiary has formally initiated the Green UAS (Uncrewed Aircraft System) certification application process for its ZenaDrone 1000 (ZD1000). The ZenaDrone Flagship product is a heavy-lift multifunction AI drone platform intended for potential inclusion on approved procurement pathways for the U.S. Department of War (DoW) and government buyers upon successful certification.“Initiating the Green UAS certification process for the ZenaDrone 1000 is a crucial step in expanding our U.S. defense and government engagement,” said Shaun Passley, Ph.D., ZenaTech CEO. “Secure, NDAA-aligned drone systems are increasingly becoming a baseline requirement for federal procurement. By advancing ZD1000 through the Green UAS pathway, our heavy-lift platform is on the path to deliver critical ISR (Intelligence, Surveillance and Reconnaissance) and cargo capabilities for defense missions. Our initiation of this application process also reinforces our commitment to cybersecurity, supply chain integrity, and American-aligned innovation.”Green UAS certification is a compliance and cybersecurity framework developed by AUVSI, the leading trade association for the uncrewed systems industry, in collaboration with the U.S. DoW. It ensures that drones are free of components from foreign adversaries and meet rigorous standards for cybersecurity, data protection, and supply chain integrity. The Green UAS certification process is expected to be streamlined for faster approvals under recent Executive Orders, which will pave the way for better alignment with Blue UAS certification, for which it is also a required precursor. Blue UAS builds on Green UAS by providing higher assurance for mission-critical defense operations. It enables streamlined DoW procurement, faster contract approvals, and deployment in sensitive or classified operational environments, ensuring certified platforms are fully trusted for defense and federal applications.The ZenaDrone 1000 is engineered as an advanced AI-powered VTOL heavy-lift platform optimized for defense use, offering ISR capabilities including real-time surveillance, tactical reconnaissance, and secure data collection, alongside cargo transport and mission-critical payload delivery. Its modular design allows rapid configuration for multi-mission operations in high-risk environments, from infrastructure monitoring to operational logistics support.About ZenaTech<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=7eIdjexGqTDgeXGH9zx3pt8hsa56bibduWPHe01VpBCUuNhIWpKrdaWMimzetVjHiGe2xeSK1HyN78hl7nw0CQ==">ZenaTech</a> (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=s2hS0ep78TNoTGg3VGcAl8R5tusMU0ve_GUCle6tLkuGwfw2nPDxwtXq_X3IkU2ekP28UEpOe2aGqf9MuzF8dIxHZ-f6Kjrc2geFQmr1uZw=">Drone as a Service</a> (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical applications for business, government and defense. Since 2017, the Company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive speed, accuracy, and cost savings. The Company operates through global offices in North America, Europe, Taiwan, and UAE, and is growing its DaaS business and global network of locations through acquisitions.About ZenaDrone<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=aRvhwzvMF23jrK70Fq3yt9MrNDgfhKMLY4R5AwiyvrU_HQymRskCy4iDLsLFpuRo4kRRR0I_fv9QW71p_E35yg==">ZenaDrone</a>, a wholly owned subsidiary of ZenaTech, develops and manufactures autonomous drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for surveying, monitoring, inspection, tracking, process automation, and defense applications. Currently, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=aRvhwzvMF23jrK70Fq3yt2BGlXzGCQlmv2Ia6qE_f7gTznMxfGQg99nXYC4Bji7ZZ7JnVZ-s1iohACL5wVTKx5tbY3eiwGqFVQ7C1pPR0OsktZ9cWZt6ECSC8Xf6WOxP">ZenaDrone 1000</a> drone is used for crop management applications and critical field cargo applications in the defense sector, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=Ov4RaVgwxqOT6SSrwGQZr3ce3BYuHaGFzUzTeVx1jRBTjJlIz1eQ6DY8O9p2C9aQV2ANAripzvXbryXE_o3el_UhT7XrD3ADkkie8qwqSJPEvIWmxiriKM-6CA-Z61mX">IQ Nano</a> indoor drone is used for inventory management and security in the warehouse and logistics sectors, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=C6zplmBVtDIqU6FoVouJBSL7Kf6GFn5u4E1VDeJaW3A6MW97CJuIoZiySSnrrNk5PN7wbyBM09Qn6vdR_kQUULpCs1Tk_tqOFunkillhs2lpAR6PtcDb4DNklrPiJFGU">IQ Square</a> is an outdoor drone designed for power washing and inspections use in commercial and government sectors, and the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=KOsgaSNLUE8q52tj484Tio5SHdDW4GdQqChJrGMz8hTuRqu0P-OLAurlzZbS2b4hs_B7Ze8cXEiobZB3beMxkVnCfkGSs_czdRYmHMbOg3s=">IQ Quad</a> is for land surveys.Contacts for more information:Company, Investors, and Media: Linda Montgomery ZenaTech 312-241-1415 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=HNwgbduylTCgzpzRwCT2XoeW6T8uErNKvMyk_e6OZed-hzF_FLRxLIy5GZdxL-LrkXOK6fz1MtqhISwvm6yXWIuEjNdgGEs65cOILjLgzsI=">investors@zenatech.com</a>Investors: Michael Mason CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=HNwgbduylTCgzpzRwCT2XoeW6T8uErNKvMyk_e6OZecQoy5f9n8I-7COdPERyqfrO3ktIw47lbqG5_DzyHhvVycrCmWLidP0kfKtI-xA0qM=">investors@zenatech.com</a>Safe HarborThis press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. &nbsp;Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity;&nbsp;ZenaTech's ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square and IQ Nano;&nbsp;ZenaTech's ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and it’s needs for additional financing;&nbsp;ZenaTech’s intention to grow the business and its operations and execution risk;&nbsp;expectations with respect to future operations and costs;&nbsp;the volatility of stock prices and market conditions in the industries in which ZenaTech operates;&nbsp;political, economic, environmental, tax, security, and other risks associated with operating in emerging markets;&nbsp;regulatory risks;&nbsp;unfavorable publicity or consumer perception;&nbsp;difficulty in forecasting industry trends;&nbsp;the ability to hire key personnel;&nbsp;the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months;&nbsp;ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments;&nbsp;investment capital and market share; the ability to complete any contemplated acquisitions;&nbsp;changes in the target markets;&nbsp;market uncertainty;&nbsp;ability to access additional capital, including through the listing of its securities in various jurisdictions;&nbsp;management of growth (plans and timing for expansion);&nbsp;patent infringement;&nbsp;litigation;&nbsp;applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks ‎‎‎and uncertainties disclosed under the ‎heading “Risk Factors“ ‎‎‎‎in the Company’s Form F-1, Form 20-F and other filings filed ‎‎‎with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=NnPNsqPhDDJe_9S_jrfBqERwD22q9iQiEgA7_D2MpQgyJceTwsF_nFBCO3CdTYNAK2UYGDBlFFeJ82bWbUOdeWVrR5EKBr2Q427HPJvikMMQYYDdqQaYMcRKPIj_m0M-KfTCzmxDtq74PG4jbE775pelEzIWzzueFRaeaxPhQ87YxWo7-Ke0HlO3FoTWjnU9ZiU_XH_Pw7Mc8PSDud8Zl836IPAS5gbkGg6egf9bgFA=">www.sec.gov</a>. The Company undertakes ‎‎‎no obligation to update forward-‎looking ‎‎‎‎information except as required by applicable law. Such forward-‎‎‎looking information represents ‎‎‎‎‎managements’ best judgment based on information currently available. ‎‎‎No forward-looking ‎‎‎‎statement ‎can be guaranteed and actual future results may vary materially. ‎‎‎Accordingly, readers ‎‎‎‎are advised not to ‎place undue reliance on forward-looking statements or ‎‎‎information.‎Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

ZenaTech’s ZenaDrone Subsidiary Initiates Green UAS Application for ZenaDrone 1000 to Strengthen U.S. Defense and Government Procurement Prospects

ZenaTech’s ZenaDrone 1000 starts Green UAS certification for U.S. government and defense contracts.

Two long and one inverse fund continue Tradr's tradition of launching first-to-market strategiesNEW YORK, Feb. 19, 2026 /PRNewswire/ -- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4622278-1&amp;h=4127592145&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>,&nbsp;a provider of ETFs designed for sophisticated investors and professional traders, today launched three new leveraged ETFs on single stocks. The Cboe-listed funds seek to deliver either two times the inverse (-200%) or two times long (200%) the daily performance of a specific underlying stock. All three ETFs are first-to-market strategies.The following ETFs are expected to open for trading today:<ul><li>Tradr 2X Short CLSK Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4622278-1&amp;h=1881570626&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fclsz&amp;a=CLSZ">CLSZ</a>) – tracks CleanSpark Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-centrus-energy-cleanspark-and-coherent-302692087.html#financial-modal">CLSK</a>)</li><li>Tradr 2X Long LEU Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4622278-1&amp;h=779022964&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fleux&amp;a=LEUX">LEUX</a>) – tracks Centrus Energy Corp. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-centrus-energy-cleanspark-and-coherent-302692087.html#financial-modal">LEU</a>)</li><li>Tradr 2X Long COHR Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4622278-1&amp;h=1653499858&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fcohx&amp;a=COHX">COHX</a>) – tracks Coherent Corp. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-centrus-energy-cleanspark-and-coherent-302692087.html#financial-modal">COHR</a>)</li></ul>"Both Coherent and Centrus are emerging participants with explosive growth potential who are supporting the buildout for AI data centers," said Matt Markiewicz, Head of Product and Capital Markets at Tradr ETFs. "The launch of CLSZ complements last September's launch of CLSX, our two-times leveraged long strategy on CleanSpark that has been well received by traders."Tradr's lineup of 69 leveraged ETFs represents over $2 billion in assets under management. Tradr's strategies can be accessed through most brokerage platforms and allow investors to avoid the hassle of using margin and the complexity of options trading. The firm continues its mission of providing sophisticated investors with innovative trading tools that enhance their ability to express market views with precision and efficiency.For detailed information on Tradr ETFs and the significant risks involved with leveraged ETFs, please visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4622278-1&amp;h=1154333248&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>.About Tradr ETFs <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4622278-1&amp;h=4127592145&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>&nbsp;are designed for sophisticated investors and professional traders&nbsp;who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs.IMPORTANT RISK INFORMATIONTradr ETFs are for sophisticated investors and professional traders with high conviction views and are very different from most other ETFs. The Funds are intended to be used as short-term trading vehicles and pursue leveraged investment objectives, which means they are riskier than alternatives that do not use leverage because the Funds magnify the performance of their underlying security. The volatility of the underlying security may affect a Fund's return as much as, or more than, the return of the underlying security.Investors in the fund should: (a) understand the risks associated with the use of leverage; (b) understand the consequences of seeking inverse and leveraged investment results; (c) for short ETFs, understand the risk of shorting; (d) intend to actively monitor and manage their investment. Fund performance will likely be significantly different than the benchmark over periods longer than the specified reset period and the performance may trend in the opposite direction than its benchmark over periods other than that period.Leverage increases the risk of a total loss of an investor's investment, may increase the volatility of the Funds, and may magnify any differences between the performance of the Funds and their reference security. The Funds seek leveraged investment results for a specific period (daily, monthly or quarterly). The exact exposure of an investment in the Fund intra-period will depend upon the movement of the reference security from the end of the prior period until the time of investment by the investor.The Fund will not attempt to position its portfolio to ensure it does not gain or lose more than a maximum percentage of its net asset value on a given trading day. As a consequence, investors in a Fund that seeks two times daily performance would lose all of their money if the Fund's underlying security moves more than 50% in a direction adverse to the Fund on a given trading day.ETFs involve risk including possible loss of the full principal value. There is no assurance that the Fund will achieve its investment objective. Principal risks and other important risks may be found in the prospectus. Past performance does not guarantee future results.ETF shares are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds. This and other important information about the Fund is contained in the Prospectus, which can be obtained by visiting <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4622278-1&amp;h=1154333248&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>. The Prospectus should be read carefully before investing.Distributed by ALPS Distributors, Inc, which is not affiliated with AXS Investments or its Tradr ETFs. AXI000868SOURCE Tradr ETFsNote: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Tradr Debuts Leveraged ETFs on Centrus Energy, CleanSpark and Coherent

Two long and one inverse fund continue Tradr's tradition of launching first-to-market strategies

All three strategies represent first-to-market exposures on growth namesNEW YORK, Feb. 18, 2026 /PRNewswire/ -- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4621801-1&amp;h=3220019750&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>,&nbsp;a provider of ETFs designed for sophisticated investors and professional traders, announced that it expects to launch three first-to-market single stock leveraged ETFs on Thursday, February 19. The Cboe-listed funds seek to deliver either two times the inverse (-200%) or two times long (200%) the daily performance of a specific underlying stock.Expected Tradr launches:<ul><li>Tradr 2X Short CLSK Daily ETF (Cboe: CLSZ) – tracks CleanSpark Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-to-launch-leveraged-etfs-on-clsk-cohr-and-leu-302691005.html#financial-modal">CLSK</a>)</li><li>Tradr 2X Long LEU Daily ETF (Cboe: LEUX) – tracks Centrus Energy Corp. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-to-launch-leveraged-etfs-on-clsk-cohr-and-leu-302691005.html#financial-modal">LEU</a>)</li><li>Tradr 2X Long COHR Daily ETF (Cboe: COHX) – tracks Coherent Corp. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-to-launch-leveraged-etfs-on-clsk-cohr-and-leu-302691005.html#financial-modal">COHR</a>)</li></ul>For detailed information on Tradr ETFs and the significant risks involved with leveraged ETFs, please visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4621801-1&amp;h=220606135&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>.About Tradr ETFs&nbsp; <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4621801-1&amp;h=3220019750&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>&nbsp;are designed for sophisticated investors and professional traders&nbsp;who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs.IMPORTANT RISK INFORMATIONTradr ETFs are for sophisticated investors and professional traders with high conviction views and are very different from most other ETFs. The Funds are intended to be used as short-term trading vehicles and pursue leveraged investment objectives, which means they are riskier than alternatives that do not use leverage because the Funds magnify the performance of their underlying security. The volatility of the underlying security may affect a Fund's return as much as, or more than, the return of the underlying security.Investors in the fund should: (a) understand the risks associated with the use of leverage; (b) understand the consequences of seeking inverse and leveraged investment results; (c) for short ETFs, understand the risk of shorting; (d) intend to actively monitor and manage their investment. Fund performance will likely be significantly different than the benchmark over periods longer than the specified reset period and the performance may trend in the opposite direction than its benchmark over periods other than that period.Leverage increases the risk of a total loss of an investor's investment, may increase the volatility of the Funds, and may magnify any differences between the performance of the Funds and their reference security. The Funds seek leveraged investment results for a specific period (daily, monthly or quarterly). The exact exposure of an investment in the Fund intra-period will depend upon the movement of the reference security from the end of the prior period until the time of investment by the investor.The Fund will not attempt to position its portfolio to ensure it does not gain or lose more than a maximum percentage of its net asset value on a given trading day. As a consequence, investors in a Fund that seeks two times daily performance would lose all of their money if the Fund's underlying security moves more than 50% in a direction adverse to the Fund on a given trading day.ETFs involve risk including possible loss of the full principal value. There is no assurance that the Fund will achieve its investment objective. Principal risks and other important risks may be found in the prospectus. Past performance does not guarantee future results.ETF shares are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds. This and other important information about the Fund is contained in the Prospectus, which can be obtained by visiting <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4621801-1&amp;h=220606135&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>. The Prospectus should be read carefully before investing.Distributed by ALPS Distributors, Inc, which is not affiliated with AXS Investments or its Tradr ETFs. AXI000870SOURCE Tradr ETFsNote: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Tradr to Launch Leveraged ETFs on CLSK, COHR and LEU

All three strategies represent first-to-market exposures on growth names

NEWPORT BEACH, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=eI7Y2CCatpgOv9GUCj8r8oz_PBqeOqOtPhMc_UNgeq1lIFHL6RE2P1pKo7tB396BbQK8UploYHCpbF3tmFmSsJMMPP-58T8DetJvYNypkOk=">Amaze Holdings, Inc.</a> (NYSE American: AMZE) (“Amaze” or the “Company), a global leader in creator-powered commerce, today announced that on February 13, 2026 it filed an amendment to its previously filed registration statement on Form S-1, which is available <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=RO9KEh7aRSyagMpzkfnDhMBhOhiEUcKcSarir2bhb7eTaZnLiFLxgjgbN3wCf4sV7gdipoJpTvm02p5Ry-_q3RXb7e6dc9nz-hmv3i70kk2wANcusjCA3KuD8HTuSq2c4g619Nwzx2QmUF9VDa4RAg==">here</a>.This amendment, which relates to the Company’s existing equity line of credit agreement, is an administrative and technical update intended to maintain an accurate and current registration statement. The filing does not reflect any material change to the Company’s business, strategy, capital structure, or previously disclosed financing arrangements. The equity line facility with C/M Capital Master Fund, LP continues to reflect substantially the same economic terms previously disclosed in the Company’s public filings.The Company currently expects the registration statement to be declared effective following the inclusion of updated financial information in its next reporting cycle, which is anticipated during the second quarter of 2026. The timing relates to the routine updating of financial statements and does not reflect any change in the Company’s plans, financing arrangements, or regulatory standing.Importantly, the filing itself does not initiate any financing transaction, does not indicate that shares have been or will be issued at this time, and does not increase the Company’s economic obligations under the equity line facility.Amaze continues to view the equity line as one of several potential capital resources and will evaluate its use based on market conditions and shareholder considerations. Any future issuances, if undertaken, will occur strictly in accordance with previously disclosed terms and applicable exchange requirements.There is no immediate operational or financial impact on shareholders arising from this administrative filing, and the Company’s strategic priorities and day-to-day operations remain unchanged.For investor information, please contact <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=WFpseC9Q1L7Xh_A7jed9VyWfFh5W5jL1Q-kl1s5D4TCzF1zkrcFVmJxjm1b59luTeKETuurG78i9g1ogYCEgqg==">IR@amaze.co</a> For press inquiries, please contact <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=7ngU4ARM3Y8M675H_P0EURUtKKjlSijup6mYTWus4d7Y9F4W5OxRWp3u00MwizysondD_UE8vzjuzbK5VOTvCw==">PR@amaze.co</a> About Amaze: Amaze Holdings, Inc. is an end-to-end, creator-powered commerce platform offering tools for seamless product creation, advanced e-commerce solutions, and scalable managed services. By empowering anyone to “sell anything, anywhere,” Amaze enables creators to tell their stories, cultivate deeper audience connections, and generate sustainable income through shoppable, authentic experiences. Discover more at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=XqNatGLxaMV9VMiKEFxgRio9N8eq0aX0m_8DkHtRU-hAcOFU2cmsSdopWiwCrA1VeTgFqbweHHN3ZWds0xEXRw==">www.amaze.co</a>.Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements relate to future events and developments or to our future operating or financial performance, are subject to risks and uncertainties and are based on estimates and assumptions. Forward-looking statements may include, but are not limited to, statements about our planned acquisitions, strategies, initiatives, growth, revenues, expenditures, the size of our market, our plans and objectives for future operations, and future financial and business performance. These statements can be identified by words such as such as “may,” “might,” “should,” “would,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue,” and are based our current expectations and views concerning future events and developments and their potential effects on us. These statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking statement. These risks include: our ability to execute our plans and strategies; our limited operating history and history of losses; our financial position and need for additional capital; our ability to attract and retain our creator base and expand the range of products available for sale; we may experience difficulties in managing our growth and expenses; we may not keep pace with technological advances; there may be undetected errors or defects in our software or issues related to data computing, processing or storage; our reliance on third parties to provide key services for our business, including cloud hosting, marketing platforms, payment providers and network providers; failure to maintain or enhance our brand; our ability to protect our intellectual property; significant interruptions, delays or outages in services from our platform; significant data breach or disruption of the information technology systems or networks and cyberattacks; risks associated with international operations; general economic and competitive factors affecting our business generally; changes in laws and regulations, including those related to privacy, online liability, consumer protection, and financial services; our dependence on senior management and other key personnel; and our ability to attract, retain and motivate qualified personnel and senior management. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other future filings and reports that we file with the Securities and Exchange Commission (SEC) from time to time. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the press release. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/NewsRoom/AttachmentNg/e5a3ffdc-3de3-4cd5-9b61-d0e5682a1931"><img src="https://ml.globenewswire.com/media/e5a3ffdc-3de3-4cd5-9b61-d0e5682a1931/small/amaze-holdings-inc-logo-jpg.jpg" alt="Primary Logo" width="150" height="38"></a>Source: Amaze Holdings, IncReleased February 17, 2026Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Amaze Announces Updated Registration Statement Filing

Amaze Holdings filed a routine, non-material administrative update to its existing equity line of credit registration.